Nelonicline - AbbVie
Alternative Names: ABT-126Latest Information Update: 05 Nov 2023
Price :
$50 *
At a glance
- Originator Abbott Laboratories
- Class Adamantanes; Aza compounds; Nootropics; Small molecules; Thiadiazoles
- Mechanism of Action Alpha7 nicotinic acetylcholine receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alzheimer's disease; Cognition disorders
Most Recent Events
- 28 Jul 2015 Phase-II development is ongoing for Cognition disorders in patients with schizophrenia
- 27 Oct 2014 AbbVie terminates long-term phase II trial in Cognition disorders in patients with schizophrenia in USA, Russia and United Kingdom (NCT01834638)
- 01 Jul 2014 AbbVie completes a phase II trial in Cognition disorders in patients with schizophrenia in the US, Russia and the UK (NCT01655680)